Company Overview of Aspireo Pharmaceuticals Ltd.
Aspireo Pharmaceuticals Ltd. develops compounds for the treatment of acromegaly and certain hormone active tumor types resulting from hypophyse disorders. It offers Somatoprim (DG3173), a novel somatostatin analogue that regulates endocrine system and affects neurotransmission and cell proliferation via interaction with G-protein-coupled somatostatin receptors and inhibition of the release of various secondary hormones. The company provides Somatoprim to treat patients with the various indications, including acromegaly, carcinoid tumors, GEP-NET, diabetic retinopathy, and cushings diseases. Aspireo Pharmaceuticals Ltd. is based in Tel Aviv, Israel.
Key Executives for Aspireo Pharmaceuticals Ltd.
Similar Private Companies By Industry
|IDEA Bio-Medical Ltd.||Middle East/Africa|
|Accelerated Evolution Biotechnologies Ltd||Middle East/Africa|
|M.M.A.Tech Ltd.||Middle East/Africa|
|PlexiCure Ltd.||Middle East/Africa|
Recent Private Companies Transactions
May 15, 2015
|Aspireo Pharmaceuticals Ltd, Somatoprim (DG3173)|
To contact Aspireo Pharmaceuticals Ltd., please visit www.aspireopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.